I-Mab 0VY.F Stock
I-Mab Price Chart
I-Mab 0VY.F Financial and Trading Overview
| I-Mab stock price | 1.6 EUR |
| Previous Close | 2.82 EUR |
| Open | 2.78 EUR |
| Bid | 2.78 EUR x N/A |
| Ask | 2.86 EUR x N/A |
| Day's Range | 2.78 - 2.78 EUR |
| 52 Week Range | 2.66 - 11.8 EUR |
| Volume | 30 EUR |
| Avg. Volume | 3 EUR |
| Market Cap | 231.96M EUR |
| Beta (5Y Monthly) | 0.97191 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.37 EUR |
0VY.F Valuation Measures
| Enterprise Value | -3140412672 EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.8911564 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | -1.0469363 |
| Price/Book (mrq) | 0.07669177 |
| Enterprise Value/Revenue | 14.174 |
| Enterprise Value/EBITDA | 1.689 |
Trading Information
I-Mab Stock Price History
| Beta (5Y Monthly) | 0.97191 |
| 52-Week Change | -69.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.8 EUR |
| 52 Week Low | 2.66 EUR |
| 50-Day Moving Average | 2.94 EUR |
| 200-Day Moving Average | 3.98 EUR |
0VY.F Share Statistics
| Avg. Volume (3 month) | 3 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 83.44M |
| Float | 38.28M |
| Short Ratio | N/A |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 64.05% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 845.79% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.21% |
| Return on Equity (ttm) | -63.73% |
Income Statement
| Revenue (ttm) | -221563008 EUR |
| Revenue Per Share (ttm) | -2.685 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -1859417984 EUR |
| Net Income Avi to Common (ttm) | -2411822080 EUR |
| Diluted EPS (ttm) | -4.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.45B EUR |
| Total Cash Per Share (mrq) | 41.56 EUR |
| Total Debt (mrq) | 74.99M EUR |
| Total Debt/Equity (mrq) | 2.49 EUR |
| Current Ratio (mrq) | 5.497 |
| Book Value Per Share (mrq) | 36.249 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of I-Mab
| Country | Germany |
| State | N/A |
| City | Shanghai |
| Address | New Bund Center |
| ZIP | 200124 |
| Phone | 86 21 6057 8000 |
| Website | https://www.i-mabbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Q&A For I-Mab Stock
What is a current 0VY.F stock price?
I-Mab 0VY.F stock price today per share is 1.6 EUR.
How to purchase I-Mab stock?
You can buy 0VY.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for I-Mab?
The stock symbol or ticker of I-Mab is 0VY.F.
Which industry does the I-Mab company belong to?
The I-Mab industry is Biotechnology.
How many shares does I-Mab have in circulation?
The max supply of I-Mab shares is 81.45M.
What is I-Mab Price to Earnings Ratio (PE Ratio)?
I-Mab PE Ratio is now.
What was I-Mab earnings per share over the trailing 12 months (TTM)?
I-Mab EPS is -2.3 EUR over the trailing 12 months.
Which sector does the I-Mab company belong to?
The I-Mab sector is Healthcare.